Denali Therapeutics Seeing Encouraging Signals From Avlayah Launch, Oppenheimer Says

MT Newswires Live05-11

Denali Therapeutics (DNLI) is seeing encouraging early launch enthusiasm for Avlayah following its recent US Food and Drug Administration approval for Hunter syndrome, Oppenheimer said in a Sunday note.

The firm said first patients were treated in a commercial setting in April, with strong interest across patient segments, geographies, and disease type.

Oppenheimer said Avlayah's approval validates Denali's streamlined development approach and could support future commercialization across the company's disease pipeline.

Startup activities remain underway for a global phase 3 study of DNL126 expected to begin in H2, while patient dosing for the phase 1 DNL952 study is expected to start soon, the firm said.

Oppenheimer maintained its outperform rating and $40 price target on Denali Therapeutics.

Price: 19.92, Change: +0.30, Percent Change: +1.53

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2634380882?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-11 23:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2634380882","market":"nz","top_or_hot":-1,"title":"Denali Therapeutics Seeing Encouraging Signals From Avlayah Launch, Oppenheimer Says","media":"MT Newswires Live","content":"<html><body><p> Denali <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (DNLI) is seeing encouraging early launch enthusiasm for Avlayah following its recent US Food and Drug Administration approval for Hunter syndrome, Oppenheimer said in a Sunday note.</p><p>The firm said first patients were treated in a commercial setting in April, with strong interest across patient segments, geographies, and disease type.</p><p>Oppenheimer said Avlayah's approval validates Denali's streamlined development approach and could support future commercialization across the company's disease pipeline.</p><p>Startup activities remain underway for a global phase 3 study of DNL126 expected to begin in H2, while patient dosing for the phase 1 DNL952 study is expected to start soon, the firm said.</p><p>Oppenheimer maintained its outperform rating and $40 price target on Denali Therapeutics.</p><p>Price: 19.92, Change: +0.30, Percent Change: +1.53</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Denali Therapeutics Seeing Encouraging Signals From Avlayah Launch, Oppenheimer Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDenali Therapeutics Seeing Encouraging Signals From Avlayah Launch, Oppenheimer Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-11 23:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Denali <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (DNLI) is seeing encouraging early launch enthusiasm for Avlayah following its recent US Food and Drug Administration approval for Hunter syndrome, Oppenheimer said in a Sunday note.</p><p>The firm said first patients were treated in a commercial setting in April, with strong interest across patient segments, geographies, and disease type.</p><p>Oppenheimer said Avlayah's approval validates Denali's streamlined development approach and could support future commercialization across the company's disease pipeline.</p><p>Startup activities remain underway for a global phase 3 study of DNL126 expected to begin in H2, while patient dosing for the phase 1 DNL952 study is expected to start soon, the firm said.</p><p>Oppenheimer maintained its outperform rating and $40 price target on Denali Therapeutics.</p><p>Price: 19.92, Change: +0.30, Percent Change: +1.53</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2634380882","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2634380882","pubTimestamp":1778512302,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Denali Therapeutics (DNLI) is seeing encouraging early launch enthusiasm for Avlayah following its recent US Food and Drug Administration approval for Hunter syndrome, Oppenheimer said in a Sunday not","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","BK4539":"次新股","BK4007":"制药","BK4535":"淡马锡持仓","BK4548":"巴美列捷福持仓","BK4139":"生物科技","BK4127":"投资银行业与经纪业","OPY":"奥本海默控股","DNLI":"Denali Therapeutics Inc."},"translate_title":"奥本海默表示，Denali Therapeutics从Avlayah的推出中看到了令人鼓舞的信号","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DNLI":1,"LENZ":1.5,"OPY":1.5},"content_text":"Denali Therapeutics (DNLI) is seeing encouraging early launch enthusiasm for Avlayah following its recent US Food and Drug Administration approval for Hunter syndrome, Oppenheimer said in a Sunday note.The firm said first patients were treated in a commercial setting in April, with strong interest across patient segments, geographies, and disease type.Oppenheimer said Avlayah's approval validates Denali's streamlined development approach and could support future commercialization across the company's disease pipeline.Startup activities remain underway for a global phase 3 study of DNL126 expected to begin in H2, while patient dosing for the phase 1 DNL952 study is expected to start soon, the firm said.Oppenheimer maintained its outperform rating and $40 price target on Denali Therapeutics.Price: 19.92, Change: +0.30, Percent Change: +1.53","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2634380882","isCrawlerRequest":true}